Meeting
2021 ASCO Annual Meeting
Identification of potential germline (GL) variants by routine clinical comprehensive genomic profiling (CGP) and confirmatory GL testing in 24 tumor types.
Authors
Kristen Hanson
Advocate Aurora Health, Milwaukee, WI
Kristen Hanson , Michael Mullane , Erica Schnettler , Dean C. Pavlick , Garrett M. Frampton , Maureen Cooper , Deborah Wham , Michael A. Thompson , Jennifer Godden , Mary Walters , Jeffrey Michael Venstrom , Kimberly McGregor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10596)
DOI
10.1200/JCO.2021.39.15_suppl.10596
Abstract #
10596
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Tumor sequencing with germline genetic testing: Identification of patients with hereditary cancer and precision treatment eligibility.
First Author: Scott T. Michalski
Poster
2022 ASCO Genitourinary Cancers Symposium
Putative germline findings in tumor-only and liquid biopsy sequencing in veterans with aggressive prostate cancer.
First Author: Kara Noelle Maxwell
Poster
2019 ASCO Annual Meeting
Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women’s Health Initiative.
First Author: Allison W. Kurian
Poster
2017 ASCO Annual Meeting
Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.
First Author: Allison W. Kurian